Skip to content
Aminoscope
Head-to-head

GHRP-1 vs GHRP-6

The prototype versus the one that actually got studied. Both are early ghrelin-receptor peptides; GHRP-6 has far more human pharmacology and a defining appetite effect.

By Julian RothResearch & dataUpdated October 2026

Short answer

GHRP-1 and GHRP-6 both have human clinical data, so the deciding factor is what you want them for. GHRP-1 suits someone focused on GH boost, while GHRP-6 is aimed at muscle and recovery. For GHRP-1, a single IV dose raised GH, peaking at 15 to 30 minutes, in 15 short children (1993); no outcome trials.

GHRP-1

Clinical data

The original GH-releasing peptide: a dose genuinely triggers a GH pulse, but that pulse is a surrogate marker — not a proven body-composition or longevity outcome — and it is unapproved.

Full GHRP-1 evidence review

GHRP-6

Clinical data

Pulses GH short-term, but its most reliable real-world effect is a surge in appetite; no long-term human outcomes and not approved.

Full GHRP-6 evidence review

GHRP-1 vs GHRP-6: head to head

FDA status / approved use

GHRP-1

Not FDA-approved; sold as a gray-market research peptide; prohibited in sport

GHRP-6

Not FDA-approved; sold as a gray-market research peptide
Marketed for

GHRP-1

GH boost, 'anti-aging'

GHRP-6

Muscle, recovery, 'anti-aging'
Outcome areas

GHRP-1

Longevity / lifespan

GHRP-6

Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan
Evidence grade

GHRP-1

Clinical data

GHRP-6

Clinical data
How it works

GHRP-1

Activates the ghrelin receptor, prompting the pituitary to release growth hormone

GHRP-6

Mimics ghrelin at its receptor, triggering a pulse of pituitary growth hormone
Route and dosing

GHRP-1

Intravenous dose in human studies; sold as gray-market vials

GHRP-6

Injection, usually subcutaneous; also studied intravenous and oral
Headline human result

GHRP-1

A single IV dose raised GH, peaking at 15 to 30 minutes, in 15 short children (1993); no outcome trials

GHRP-6

GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome data
Strongest evidence

GHRP-1

Laron, Acta Endocrinol 1993GHRP-1 evidence reviewPubMed 8279223
Key safety signal

GHRP-1

No long-term human safety data; expected appetite, cortisol and prolactin effects

GHRP-6

Strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing
How it is obtained

GHRP-1

Sold gray-market as a research chemical; no approved or legitimately compounded human product

GHRP-6

Sold gray-market as a research chemical; no approved or legitimately compounded human product

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

GHRP-1 does what its class does: an intravenous bolus produced a progressive rise in plasma GH peaking within about 15 to 30 minutes in healthy children and adolescents, with a larger response in pubertal than prepubertal subjects. GHRP-6 has broader human characterization, with GH release documented across intravenous, subcutaneous, intranasal and oral routes, plus a strong dose-dependent appetite effect and a measurable rise in ACTH and cortisol. Both stop at the surrogate marker; there are no long-term human outcome trials behind the fat-loss, muscle or anti-aging claims for either. Neither is approved, both are research-only, and both are prohibited in sport.

GHRP-1 fits if

GHRP-1 is mostly of historical interest, relevant to a reader tracing where this peptide family started; almost everything specific about GHRP dosing and side effects comes from its descendants.

GHRP-6 fits if

GHRP-6 is the more informative read, since its human pharmacology is broader and its appetite effect is the clearest signal it reliably produces.

GHRP-1 vs GHRP-6: common questions

Is either GHRP-1 or GHRP-6 FDA-approved?
No. GHRP-1 is not FDA-approved; sold as a gray-market research peptide; prohibited in sport. GHRP-6 is not FDA-approved; sold as a gray-market research peptide.
Which has stronger human evidence, GHRP-1 or GHRP-6?
Neither clearly. Both have human clinical data. The key source for GHRP-1 is Laron, Acta Endocrinol 1993; for GHRP-6, it is Jaffe, JCEM 1993.
What are the main safety concerns with GHRP-1 and GHRP-6?
GHRP-1 has no long-term human safety data; expected appetite, cortisol and prolactin effects. For GHRP-6, watch for strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing.

Key studies behind each

GHRP-1

  1. Laron Z, Bowers CY, Hirsch D, Almonte AS, Pelz M, Keret R, Gil-Ad I. (1993). Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents. Acta Endocrinol (Copenh). PubMed 8279223
  2. Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. PubMed 9893708
  3. Laron Z. (1995). Growth hormone secretagogues. Clinical experience and therapeutic potential. Drugs. PubMed 8536548
  4. Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal. PubMed 25869809

GHRP-6

  1. Frieboes RM, Murck H, Maier P, et al. (1995). Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. PubMed 7617137
  2. Jaffe CA, Ho PJ, Demott-Friberg R, et al. (1993). Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. PubMed 7903313
  3. Frieboes RM, Murck H, Antonijevic IA, et al. (1999). Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol. PubMed 10336729
  4. Bellone J, Ghizzoni L, Aimaretti G, et al. (1995). Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. PubMed 7581965

The full evidence reviews

  • GHRP-1: the original GH secretagogue, and why a real GH pulse still isn't proof

    GHRP-1 is one of the earliest synthetic growth-hormone-releasing peptides and the forerunner of GHRP-2 and GHRP-6. A single dose genuinely releases growth hormone — but that pulse is a short-term surrogate marker, not an outcome, and there are no long-term human trials behind its anti-aging marketing.

    Updated August 2026

  • GHRP-6: the 'hunger' growth-hormone secretagogue, and what the evidence shows

    GHRP-6 is a first-generation ghrelin-receptor agonist that pulses growth hormone — but its most reliable real-world effect is a strong, dose-dependent surge in appetite. Real short-term GH pharmacology, preclinical cytoprotection, no long-term human outcomes, and not FDA-approved.

    Updated August 2026

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm GHRP-1 availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 204 peptide-therapy providers →

Provider reviews we publish: RxION HealthOurView HealthPauseRXPepHaūsPeptidesRxPlexusDx

Related comparisons